PSEUDO-12

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PSEUDO-12 (PSEUDO-12).

How it works

Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.

What the body does with it

Metabolism	Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
Excretion	Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Half-life	Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Protein binding	Binding: 30-40%; primarily to albumin.
Volume of Distribution	Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
Bioavailability	Oral: 90-100% (immediate-release); 80-90% (extended-release).
Onset of Action	Oral: 30 minutes (immediate-release); 1-2 hours (extended-release).
Duration of Action	Oral: 4-6 hours (immediate-release); 12 hours (extended-release). Tolerance may develop with prolonged use.

Classification & Brands

Dosing & administration

60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.

Dosage form	SUSPENSION, EXTENDED RELEASE
Renal impairment	eGFR 30-50 mL/min: 30 mg every 6 hours as needed; maximum 120 mg/day. eGFR <30 mL/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Pediatric use	Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Geriatric use	Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PSEUDO-12 (PSEUDO-12).

Breastfeeding	Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.

Clinical Precautions

Precautions

Cardiovascular effects: hypertension, palpitations, arrhythmias; CNS stimulation: insomnia, anxiety, tremor; exacerbation of glaucoma, hyperthyroidism, diabetes; urinary retention in prostatic hypertrophy; rebound congestion with prolonged use.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PSEUDO-12

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PSEUDO-12 (PSEUDO-12).

How it works

Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.

What the body does with it

Metabolism	Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
Excretion	Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Half-life	Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Protein binding	Binding: 30-40%; primarily to albumin.
Volume of Distribution	Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
Bioavailability	Oral: 90-100% (immediate-release); 80-90% (extended-release).
Onset of Action	Oral: 30 minutes (immediate-release); 1-2 hours (extended-release).
Duration of Action	Oral: 4-6 hours (immediate-release); 12 hours (extended-release). Tolerance may develop with prolonged use.

Classification & Brands

Dosing & administration

60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.

Dosage form	SUSPENSION, EXTENDED RELEASE
Renal impairment	eGFR 30-50 mL/min: 30 mg every 6 hours as needed; maximum 120 mg/day. eGFR <30 mL/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Pediatric use	Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Geriatric use	Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PSEUDO-12 (PSEUDO-12).

Breastfeeding	Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.